Lynn Cadovius
About Lynn Cadovius
Lynn Cadovius serves as the Director of Strategic Alliances and Global Project Management at Celerion, bringing over 25 years of experience in the pharmaceutical and clinical research industry.
Work at Celerion
Lynn Cadovius has been with Celerion since 2010, holding various positions that demonstrate her expertise in global project management. She currently serves as the Director of Strategic Alliances, Global Project Management, a role she has occupied since 2018. Prior to this position, she was the Director of Global Project Management from 2016 to 2018 and the Associate Director of Global Project Management from 2015 to 2016. Her career at Celerion reflects a steady progression in responsibilities and leadership within the organization.
Education and Expertise
Lynn Cadovius has a solid educational background in health science and business management. She studied Health Science at both Champlain College and Vanier College. Additionally, she earned a Bachelor of Science in Business Management from the University of Phoenix, where she studied from 2001 to 2007. This combination of education equips her with a comprehensive understanding of both the clinical research and business aspects of the pharmaceutical industry.
Background
With over 25 years of experience in the pharmaceutical and clinical research industry, Lynn Cadovius has developed a robust career. Before joining Celerion, she worked at Mds Pharma Services as a Senior Global Project Manager in Early Clinical Research for 12 years. She also held a leadership role at AmerisourceBergen Specialty Group Canada, further enhancing her expertise in project management and strategic alliances within the healthcare sector.
Achievements
Lynn Cadovius has received recommendations from three different individuals, highlighting her professional contributions in the field. Her extensive experience and leadership roles in various organizations underscore her commitment to excellence in project management and strategic alliances within the pharmaceutical industry.